Company intelligence / Profile preview

ArtBlood

Seoul, Seoul, South Korea

Ownership: Private
Development stage: Other

Overview

ArtBlood has developed the BioBlood cultured red blood cell product, which mimics native blood. It offers advantages such as universal compatibility, reduced infection risks, and longer circulation. The company is progressing toward mass production, having secured Series A funding and signed major manufacturing partnerships for clinical development.

Therapeutic areas: Hematology
Modalities: Cell therapyBiologic
Industry: Biotech

Partnerships

Expression Manufacturing LLC / Expression Therapeutics, Inc. (large-scale cGMP manufacturing partnership)

Beyond the preview

Go deeper on ArtBlood.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ArtBlood.

Explore the full profile